‘It’s a smart missile’: the Italian super-expert explains the new drug that slows Alzheimer’s

“This is great news for patients, for their families and also for science.” Thus begins the professor Paolo M. Rossini, director of neurology at the Ircss San Raffaele in Rome, at the request to comment on the approval by the American Food and Drug Administration of the first drug against Alzheimer’s, Aducanumab, trade name Aduhelm. An approval around which doubts and controversies revolve also given the contrary opinion of the independent committee of the American agency, according to which there is not enough evidence that the drug can really help patients.